Literature DB >> 8242662

Tumor idiotype vaccines. VIII. Analysis of protective idiotype in sera and hybridomas derived from tumor-bearing mice with long-term survival.

J J Chen1, H Kohler.   

Abstract

In this study, the contribution of idiotype-positive antitumor antibodies (anti-Id) in protective tumor immunity was investigated. We have previously shown that among various anti-Id generated and typed as the internal-image Ab2 of the tumor-associated antibody (TAA) gp52, only 2F10 antibody induces protective immunity. Increase of the 2F10 idiotope in sera of tumor-bearing mice correlated with long-term survival, while in mice with short survival the circulating 2F10 idiotype decreased. 2F10+ Ig were purified from sera of tumor-bearing mice with long-term survival and the amount of 2F10+ anti-TAA antibodies was determined. Only about 3% of 2F10+ antibodies are 2F10+ anti-TAA+. Hybridomas were generated from a 2F10 high mouse with spontaneous tumor regression. Only 2 out of 52 tumor-specific hybridomas were 2F10+. These results suggest that the protective effect induced by 2F10 vaccination may not be directly mediated by 2F10+ antibodies but indirectly through the stimulation of a 2F10-specific cellular immune response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242662     DOI: 10.1007/bf01526793

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  16 in total

1.  Tumor-specific idiotype vaccines. III. Induction of T helper cells by anti-idiotype and tumor cells.

Authors:  S Raychaudhuri; Y Saeki; J J Chen; H Kohler
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

2.  Characterization of "regulatory" idiotope-specific T cell clones to a monoclonal anti-idiotypic antibody mimicking a tumor-associated antigen (TAA).

Authors:  Y Saeki; J J Chen; L F Shi; S Raychaudhuri; H Köhler
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

3.  Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens.

Authors:  H Fuji; H Iribe
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

4.  Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen.

Authors:  M Bhattacharya-Chatterjee; S Mukerjee; W Biddle; K A Foon; H Köhler
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

5.  Monoclonal anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen: generation and characterization of anti-idiotype antibodies.

Authors:  P Chattopadhyay; D Sneed; J Rosenberg; J Starkey; N Robertson; J Leonard; S Raychaudhuri
Journal:  Cancer Res       Date:  1991-06-15       Impact factor: 12.701

6.  Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic, and biologic properties of protective and nonprotective Ab2.

Authors:  S Raychaudhuri; C Y Kang; S V Kaveri; T Kieber-Emmons; H Köhler
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

7.  Idiotype vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotopes.

Authors:  M Bhattacharya-Chatterjee; M W Pride; B K Seon; H Kohler
Journal:  J Immunol       Date:  1987-08-15       Impact factor: 5.422

8.  Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta).

Authors:  S Raychaudhuri; Y Saeki; J J Chen; H Iribe; H Fuji; H Kohler
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

9.  Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.

Authors:  L Rapp; H Fuji
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.

Authors:  A Lanzavecchia; S Abrignani; D Scheidegger; R Obrist; B Dörken; G Moldenhauer
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.